Hologic (NASDAQ:HOLX) had its target price lifted by Piper Jaffray Companies from $49.00 to $59.00 in a research note issued to investors on Thursday, August 1st, The Fly reports. The firm currently has an overweight rating on the medical equipment provider’s stock.
A number of other equities research analysts have also commented on HOLX. ValuEngine upgraded Hologic from a hold rating to a buy rating in a research report on Tuesday, June 11th. BidaskClub raised Hologic from a hold rating to a buy rating in a report on Saturday, July 27th. BTIG Research reissued a buy rating and issued a $52.00 price target on shares of Hologic in a report on Thursday, August 1st. Needham & Company LLC reissued a buy rating and issued a $57.00 price target (up from $52.00) on shares of Hologic in a report on Thursday, August 1st. Finally, Zacks Investment Research raised Hologic from a hold rating to a buy rating and set a $46.00 price target for the company in a report on Wednesday, May 29th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $48.94.
NASDAQ HOLX traded down $1.71 during trading hours on Thursday, reaching $48.13. The stock had a trading volume of 1,523,586 shares, compared to its average volume of 1,572,031. The stock has a fifty day moving average of $49.19 and a 200 day moving average of $47.07. The stock has a market cap of $13.33 billion, a P/E ratio of 21.58, a price-to-earnings-growth ratio of 2.26 and a beta of 0.74. Hologic has a 52-week low of $37.47 and a 52-week high of $52.19. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.11 and a current ratio of 1.57.
In other news, Chairman Stephen P. Macmillan sold 194,396 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $48.77, for a total transaction of $9,480,692.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peter J. Valenti III sold 4,545 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $44.07, for a total value of $200,298.15. The disclosure for this sale can be found here. Insiders own 0.90% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its stake in Hologic by 0.5% in the 2nd quarter. BlackRock Inc. now owns 18,609,553 shares of the medical equipment provider’s stock valued at $893,630,000 after purchasing an additional 95,737 shares during the last quarter. Natixis acquired a new position in Hologic in the 2nd quarter valued at $4,191,000. Colony Group LLC acquired a new position in Hologic in the 2nd quarter valued at $1,288,000. Royal Bank of Canada raised its stake in Hologic by 59.2% in the 2nd quarter. Royal Bank of Canada now owns 132,671 shares of the medical equipment provider’s stock valued at $6,372,000 after purchasing an additional 49,330 shares during the last quarter. Finally, UBS Group AG grew its holdings in Hologic by 18.7% in the 2nd quarter. UBS Group AG now owns 356,495 shares of the medical equipment provider’s stock valued at $17,119,000 after buying an additional 56,156 shares in the last quarter. 96.17% of the stock is owned by institutional investors and hedge funds.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Read More: What is a growth and income fund?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.